Shamburg News · 8-K filed Nov 12, 2026, 4:10 PM EST
Lineage Cell Therapeutics Completes NeuroAirmid Acquisition and Reports Q3 2026 Results
LCTX · Lineage Cell Therapeutics, Inc.
- Acquisition
- Material agreement
- Earnings
- Reg FD disclosure
- Materiality: high
On November 12, 2026, Lineage Cell Therapeutics acquired all outstanding shares of NeuroAirmid Therapeutics from its stockholders, which became a wholly owned subsidiary; closing consideration included $2.4 million in cash and 2.2 million Lineage common shares, with up to $48.0 million in contingent milestone payments. NeuroAirmid's HUNT1 program is in the Phase 1b/2a REGEN4HD study for Huntington's Disease, and its license from The Regents of the University of California was amended and restated. Lineage also reported third quarter 2026 results, with total revenues of approximately $1.5 million and net income attributable to Lineage of $4.2 million, or $0.02 basic and ($0.03) diluted per share.
Source: SEC EDGAR, Form 8-K, Items 1.01, 2.01, 2.02, 3.02, 7.01, accession 0001193125-26-458377.
Written from the filing by Shamburg Markets. Figures are as reported by the company.